Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net income	$ 1,610.3	$ 2,017.6
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation, amortization and acquired in-process research and development	814.6	325.1
Share-based compensation	67.3	84.1
Deferred income taxes	(20.5)	(30.2)
Other	73.5	28.9
Changes in operating assets and liabilities, net:
Accounts receivable	(301.2)	(65.0)
Inventory	(85.3)	(128.3)
Accrued expenses and other current liabilities	(452.3)	(116.4)
Income tax assets and liabilities	(114.7)	(76.7)
Other changes in operating assets and liabilities, net	(187.3)	(25.1)
Net cash flows provided by operating activities	1,404.4	2,014.0
Cash flows from investing activities:
Proceeds from sales and maturities of marketable securities	3,584.5	2,823.6
Purchases of marketable securities	(2,536.0)	(3,833.3)
Contingent consideration related to Fumapharm AG acquisition	600.0	600.0
Acquired in-process research and development	(120.0)	0.0
Purchases of property, plant and equipment	(407.7)	(263.7)
Acquisitions of intangible assets	(860.3)	0.0
Other	(7.3)	(65.9)
Net cash flows used in investing activities	(946.8)	(1,939.3)
Cash flows from financing activities:
Purchases of treasury stock	(1,365.4)	0.0
Payments related to issuance of stock for share-based compensation arrangements, net	(17.8)	(21.9)
Net cash contribution to Bioverativ Inc.	302.7	0.0
Other	33.5	1.1
Net cash flows used in financing activities	(1,652.4)	(20.8)
Net (decrease) increase in cash and cash equivalents	(1,194.8)	53.9
Effect of exchange rate changes on cash and cash equivalents	37.8	0.1
Cash and cash equivalents, beginning of the period	2,326.5	1,308.0
Cash and cash equivalents, end of the period	$ 1,169.5	$ 1,362.0